The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1427
October 14, 2013
View Complete Issue         Table of Contents 2019 
Brimonidine Gel (Mirvaso) for Rosacea
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Brimonidine Gel (Mirvaso) for Rosacea
October 14, 2013 (Issue: 1427)
The FDA has approved the selective alpha2-adrenergic receptor agonist brimonidine as a 0.33% gel (Mirvaso – Galderma) for topical treatment of adults with persistent facial erythema of rosacea. Brimonidine is also available in ophthalmic...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Brimonidine Gel (Mirvaso) for Rosacea
Article code: 1427b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.